

A2

At page 71, at the end of the specification, before the claims, delete the previously filed Sequence Listing and insert the printed Sequence Listing submitted herewith.

Please renumber claim pages 122-129 sequentially after the Sequence Listing submitted concurrently herewith.

~~32. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition,~~

wherein the pharmaceutical composition comprises an antibody to lipoteichoic acid of Gram positive bacteria, or fragment, region, or derivative thereof, and a pharmaceutically acceptable carrier, and

wherein the antibody, fragment, region, or derivative thereof

(a) binds to lipoteichoic acid at a level that is twice background or greater, and

(b) enhances the opsonization of Gram positive bacteria by 75% or more.

33. The method of claim 32, ~~wherein~~ the antibody is a monoclonal antibody.

34. The method of claim 33, wherein the monoclonal antibody is MAB 96-110.

35. The method of claim 34, wherein MAB 96-110 is chimeric and humanized.

00000000

A3

Sub
C1

INNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

36. The method of claim 32, wherein the antibody, fragment, region, or derivative thereof binds to a peptide sequence chosen from:

W R M Y F S H R H A H L R S P (SEQ ID NO: 1) and

W H W R H R I P L Q L A A G R (SEQ ID NO: 2).

37. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises an antibody to lipoteichoic acid of Gram positive bacteria, or fragment, region, or derivative thereof, and a pharmaceutically acceptable carrier, and

wherein the antibody, fragment, region, or derivative thereof bind to a peptide sequence chosen from:

W R M Y F S H R H A H L R S P (SEQ ID NO: 1) and

W H W R H R I P L Q L A A G R (SEQ ID NO: 2).

38. The method of claim 37, wherein the antibody is a monoclonal antibody.

39. The method of claim 38, wherein the monoclonal antibody is MAB 96-110.

40. The method of claim 39, wherein MAB 96-110 is chimeric and humanized.

41. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises a lipoteichoic acid epitope peptide mimic, and a pharmaceutically acceptable carrier, and

wherein the peptide mimic is a peptide sequence chosen from:

Sub
C1

09893615-062901

A3

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

- (a) W R M Y F S H R H A H L R S P (SEQ ID NO: 1);
- (b) W H W R H R I P L Q L A A G R (SEQ ID NO: 2); and
- (c) peptide sequences that are substantially homologous to the sequences of (a) or (b).

42. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises a peptide encoded by DNA of the variable region of the anti-lipoteichoic acid antibody of Figure 12, or by a sequence that is at least 70% homologous to that DNA, and a pharmaceutically acceptable carrier.

43. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises a peptide characterized by amino acids corresponding to one or more of the Complementarity Determining Regions of the variable regions of the anti-lipoteichoic acid antibody of Figure 12, or amino acids that are at least 70% homologous to the Complementarity Determining Regions.

44. The method of claim 43, wherein the Complementarity Determining Regions are derived from MAB 96-110.

IN THE DRAWINGS:

Subject to the approval of the Examiner, please replace the current Figure 12 with the attached substitute Figure 12.